Compare IGD & CYRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IGD | CYRX |
|---|---|---|
| Founded | N/A | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 449.6M | 472.7M |
| IPO Year | N/A | N/A |
| Metric | IGD | CYRX |
|---|---|---|
| Price | $5.71 | $10.73 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $12.83 |
| AVG Volume (30 Days) | 215.3K | ★ 441.3K |
| Earning Date | 01-01-0001 | 11-04-2025 |
| Dividend Yield | ★ 9.15% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 1.27 |
| Revenue | N/A | ★ $243,795,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $9.26 |
| P/E Ratio | ★ N/A | $7.92 |
| Revenue Growth | N/A | ★ 41.27 |
| 52 Week Low | $4.60 | $4.58 |
| 52 Week High | $5.26 | $11.44 |
| Indicator | IGD | CYRX |
|---|---|---|
| Relative Strength Index (RSI) | 42.03 | 71.02 |
| Support Level | $5.66 | $9.44 |
| Resistance Level | $5.88 | $9.87 |
| Average True Range (ATR) | 0.05 | 0.37 |
| MACD | -0.02 | 0.08 |
| Stochastic Oscillator | 21.84 | 97.35 |
Voya Global Equity Dividend and Premium Opportunity Fund are a United States-based diversified, closed-end Fund. The primary objective of the Fund is to seek to provide investors with a high level of income from a portfolio of common stocks with historically attractive dividend yields and premiums from call option writing. The secondary investment objective of the company is capital appreciation. Under normal market conditions, the Fund will invest at least 80% of its managed assets in a portfolio of common stocks of dividend-paying companies located throughout the world.
CryoPort Inc is a leader serving the life sciences industry as a provider of integrated temperature-controlled supply chain solutions supporting the life sciences in the biopharma/pharma, animal health, and reproductive medicine markets. It operates in two reportable segments: Life Sciences Services and Life Sciences Products. Geographically the company operates in the Americas, Europe, the Middle East and Africa (EMEA), and Asia Pacific (APAC), generating a majority of its revenue from the Americas.